Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.40 |
| ▸ | GYS1 | P13807 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287834 | 0.85 | KDM4E (0.41) | GAAMEN1KMT2A | |
| SCHEMBL4301418 | 0.83 | FFAR4 (0.37) | FFAR4GYS1GAAMEN1LMNA | |
| SCHEMBL4286594 | 0.80 | LMNA (0.50) | GAAMEN1LMNAKMT2A | |
| SCHEMBL4295523 | 0.79 | HCRTR1 (0.36) | — | |
| SCHEMBL4286428 | 0.74 | HCRTR1 (0.47) | GAA | |
| SCHEMBL4284654 | 0.74 | CPS1 (0.44) | MEN1KMT2AGPR119 | |
| SCHEMBL4285580 | 0.74 | CPS1 (0.46) | LMNA | |
| SCHEMBL4281389 | 0.74 | RBP4 (0.38) | GAALMNAKMT2A | |
| SCHEMBL4290686 | 0.73 | ENPP2 (0.43) | — | |
| SCHEMBL3494366 | 0.73 | TEAD1 (0.50) | GAAMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | FFAR4 3121/4885GYS1 3879/4885GAA 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.